Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165923 | 0.94 | CXCR4 (0.50) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL19410287 | 0.92 | CXCR4 (0.48) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21812908 | 0.92 | CXCR4 (0.48) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL12501275 | 0.86 | CXCR4 (0.63) | CXCR4SIGMAR1POLBSMN1; SMN2ALOX15 | |
| SCHEMBL2912801 | 0.85 | ALDH1A1 (0.45) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL19604 | 0.85 | ALDH1A1 (0.45) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6151027 | 0.83 | ALDH1A1 (0.44) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| Piperazine SCHEMBL27980522 | 0.83 | CXCR4 (0.47) | CXCR4SIGMAR1POLBSMN1; SMN2ALDH1A1 | |
| Carbamic Acid SCHEMBL8817104 | 0.82 | SIGMAR1 (0.41) | CXCR4SIGMAR1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL8614873 | 0.82 | CXCR4 (0.70) | CXCR4SIGMAR1POLBSMN1; SMN2GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4223761-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2212363-A1 | METHOD FOR PRODUCING CELLULAR POLYURETHANE (PURE) CAST ELASTOMERS FROM SHELF-STABLE 1,5-NAPHTHALENE DIISOCYANATE (NDI) PREPOLYMERS | Bayer MaterialScience AG (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009062672-A1 | METHOD FOR PRODUCING CELLULAR POLYURETHANE (PURE) CAST ELASTOMERS FROM SHELF-STABLE 1,5-NAPHTHALENE DIISOCYANATE (NDI) PREPOLYMERS | BAYER MATERIALSCIENCE AG (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-1379568-A1 | CELLULAR POLYISOCYANATE POLYADDITION PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002081537-A1 | CELLULAR POLYISOCYANATE POLYADDITION PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CXCR4 2075/4885SIGMAR1 1269/4885POLB 930/4885 |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | CXCR4 220/4885SIGMAR1 606/4885POLB 2370/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | CXCR4 210/4885SIGMAR1 561/4885POLB 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.